RxDoctor Payments Data

Erica Stokes, MD

Family Medicine · Boynton Beach, FLNPI 1669812178

Payments from drug & device makers

$1,783in general payments, 2019–2025

Across 86 payments — averaging $20.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$317
  • Biohaven Pharmaceuticals, Inc.$177
  • VB Spine LLC$164
  • Pfizer$163
  • Abbott$148
  • Novo Nordisk$138
  • plus $676 from 16 others

What the payments were for

  • Food & beverage$1,781100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,783 in reported general payments places this provider in the 70th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$5,794
Medicare patients
22
Services billed
98

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide28$31,255
OzempicSemaglutide22$22,455
JardianceEmpagliflozin23$20,332
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$2,334
Levothyroxine Sodium55$908
Atorvastatin Calcium105$689
Losartan Potassium61$628
Gabapentin57$621
Rosuvastatin Calcium37$612
Montelukast Sodium39$597
Mirtazapine23$557
Albuterol Sulfate HfaAlbuterol Sulfate24$460
Trazodone Hcl21$441
Nifedipine ErNifedipine13$423
Pantoprazole Sodium31$409

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$70$31,25528 claims
Novo NordiskOzempic$138$22,45522 claims
Boehringer IngelheimJardiance$12$20,33223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Boynton Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →